PlaqueTec has a proprietary device with unique capability to take simultaneous in-vivo blood samples from either side of a coronary plaque, collecting biomolecules localising at the disease site.
Via extensive comparative analysis of upstream and downstream samples, a novel biochemical interpretation of disease can be generated for each patient.
Combining plaque biochemical insights with imaging, genetic, clinical and demographic data enables us to identify patient cohorts with distinct disease biology.
Endotyping disease in this way, alongside the quantification of thousands of disease-site biomolecules provides a unique platform for the identification of therapeutic targets and development of precision medicines.
What we do:
Improving prospects for patients with coronary artery disease through:
Existing therapies for patients suffering with CAD largely consider patients as one uniform population, who all undergo standardised risk factor optimisation to reduce their risk of progression to an acute event and need for surgical coronary intervention.
This approach has shown benefits, however as the data above suggest, huge residual risk remains. A better disease and patient specific understanding is required to enable the development of a new wave of precision medicines for identifiable CAD sub-types with certain disease morphology and clinical risk profiles.
Our mission is to provide this understanding and pursue the development of precision therapeutics to improve the prospects for millions of patients suffering with CAD.
The need for precision medicine in CAD
Cardiovascular disease (CVD) is the leading cause of death worldwide, and Coronary Artery Disease (CAD) is the most common type of CVD, accounting for 49% of the 18.6 million CVD-related deaths in 2019. In the U.S., the total direct medical costs associated with CVD were $318 billion in 2015, and are projected to reach $749 billion by 2035.
Why target CAD?
Global trends in number of deaths due to cardiovascular diseases, 1990-2019